Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | OSBP | P22059 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | UGCG | Q16739 | 2/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435883 | 1.00 | PLA2G2A (0.62) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL16172138 | 1.00 | PLA2G2A (0.62) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL19115392 | 0.95 | POLA1 (0.61) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL16158084 | 0.94 | POLA1 (0.62) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL26033570 | 0.93 | POLA1 (0.59) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL23876215 | 0.93 | POLA1 (0.68) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL12325985 | 0.92 | CYP46A1 (0.68) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL20620339 | 0.92 | POLA1 (0.62) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL12349259 | 0.91 | POLA1 (0.65) | PLA2G2APOLA1CYP46A1USP2LMNA | |
| SCHEMBL24435914 | 0.91 | POLA1 (0.65) | PLA2G2APOLA1CYP46A1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | PLA2G2A 284/4885POLA1 29/4885CYP46A1 958/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | PLA2G2A 23/4885POLA1 4444/4885CYP46A1 92/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | PLA2G2A 33/4885POLA1 4028/4885CYP46A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.